Arcellx's cell therapy is on hold after patient death in multiple myeloma trial
Arcellx said its autologous cell therapy was put on hold last Friday after the death of a recent patient in a trial testing the biotech’s CAR-modified T cell therapy in relapsed or refractory multiple myeloma.
The hold impacts Arcellx’s lead program, which is also part of Gilead’s bet that it can commercialize additional cell therapies following the success of its Kite unit. The biopharma contributed $225 million upfront on the program late last year, around the time initial data came out at the annual American Society of Hematology meeting.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
